China Pharma in MENA: The Complete Deal Tracker & Strategic Outlook
EPT Research · 15 Aug 2026
The "China discount" on licensing upfronts is still 60–70% below Western assets. But it's narrowing fast.
Early movers — Hikma, Julphar, PDC, KGbio — are building regional franchises around Chinese innovation. The next wave will be NewCos (spin-off vehicles), co-development deals , and manufacturing JVs backed by Saudi and UAE sovereign capital.
Full deal tracker and strategic analysis in the report below 👇